In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

The State of Indiana won’t pay property taxes for 9,000 acres it has bought in Boone County because state and non-profit ...

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

The United States Federal Trade Commission (FTC) filed an administrative complaint against the nation’s three largest ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

CHICAGO -- Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the ...

Indiana University analysis suggests that aggregate health care spending in the state is on par with peers in other states, but that Hoosiers are more likely ...

The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...

Tesla (TSLA 3.07%) is back. Shares of the electric vehicle (EV) maker plunged as much as 43% earlier this year. The stock has been on a roll since late April, though, soaring more ...